RVTY
REVVITY, INC.
Overview
Revvity provides instruments, reagents, software and services for life sciences research and clinical diagnostics. Its Life Sciences segment offers products for drug discovery and development, including assay technologies, imaging systems, liquid handlers and analysis software used by pharmaceutical, biotech and academic researchers.
REVVITY, INC is a Healthcare company operating in Diagnostics & Research with a $11.05B market cap.
Most recent reported earnings: Q2 FY2026 (Jul 26, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0514 Q&A exchanges
- Q4 FY2025Earnings2026-02-0219 Q&A exchanges
- Q3 FY2025Earnings2025-10-2726 Q&A exchanges
- Q2 FY2025Earnings2025-07-2821 Q&A exchanges
- Q1 FY2025Earnings2025-04-2827 Q&A exchanges
- Q4 FY2024Earnings2025-01-3129 Q&A exchanges
- Q3 FY2024Earnings2024-11-0434 Q&A exchanges
- Q2 FY2024Earnings2024-07-2937 Q&A exchanges
- Q1 FY2024Earnings2024-04-2923 Q&A exchanges
- Q4 FY2023Earnings2024-02-0121 Q&A exchanges
- Q3 FY2023Earnings2023-11-0540 Q&A exchanges
- Q2 FY2023Earnings2023-08-0639 Q&A exchanges
- Q1 FY2023Earnings2023-05-111 Q&A exchange
- Q4 FY2022Earnings2023-02-1439 Q&A exchanges
- Q3 FY2022Earnings2022-11-0831 Q&A exchanges
- Q2 FY2022Earnings2022-08-0519 Q&A exchanges
- Q1 FY2022Earnings2022-05-0334 Q&A exchanges
- Q4 FY2021Earnings2022-02-0134 Q&A exchanges
- Q3 FY2021Earnings2021-11-0218 Q&A exchanges
- Q2 FY2021Earnings2021-07-2829 Q&A exchanges
- Q1 FY2021Earnings2021-05-0530 Q&A exchanges
History
Earnings history
- Q2 FY20262026-07-26EPS— vs $1.22—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-07-26 | — | $1.22 | — | — | — | — | EODHD |
Source: EODHD. RVTY reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks RVTY's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 60% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.91 | $2.44 | +19.2% | -5.5% | -8.0% |
| Q4 FY2026 | $3.05 | $2.50 | +22.2% | +5.4% | +5.4% |
| Q3 FY2026 | $2.93 | $2.52 | +16.4% | +4.7% | +1.8% |
| Q2 FY2026 | $3.29 | $2.66 | +23.7% | -3.3% | -1.7% |
| Q1 FY2025 | $3.14 | $2.54 | +23.8% | -3.8% | -2.4% |
| Q4 FY2025 | $2.90 | $2.58 | +12.5% | +3.0% | +1.7% |
| Q3 FY2025 | $3.54 | $2.79 | +26.9% | +1.4% | -1.3% |
| Q2 FY2025 | $3.52 | $2.81 | +25.4% | -3.7% | -1.0% |
| Q1 FY2024 | $3.27 | $2.62 | +24.7% | +5.8% | +8.4% |
| Q4 FY2024 | $3.36 | $2.87 | +16.9% | +4.7% | +2.0% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Anita GonzalesVice President and CAO2 mono recorded callsCurrentSample
OTHER since 2026 • 1/2 beats (50%) • guidance suspended Q2 FY2026
- Joel S GoldbergPlease See Remarks4 mono recorded callsCurrentSample
OTHER since 2026 • 1/2 beats (50%) • guidance suspended Q1 FY2026
- Prahlad R SinghPlease See Remarks8 mo21 callsCurrentSample
OTHER since 2025 • 3/4 beats (75%) • last guidance raise Q2 FY2026
- Tajinder S VohraPlease See Remarks10 mono recorded callsCurrentSample
OTHER since 2025 • 3/4 beats (75%) • last guidance cut Q1 FY2026
- Miriame VictorPlease See Remarks10 mono recorded callsCurrentSample
OTHER since 2025 • 2/4 beats (50%) • guidance suspended Q1 FY2026
- Maxwell KrakowiakPlease See Remarks1 yr 4 mo6 callsCurrentSample
OTHER since 2025 • 3/4 beats (75%) • last guidance cut Q3 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for RVTY.
$ curl https://api.spokenalpha.com/v1/companies/RVTYFAQ
Frequently asked about RVTY
Where can I find REVVITY, INC.'s (RVTY) earnings call transcripts?
Spoken Alpha indexes RVTY's earnings call transcripts at https://spokenalpha.com/companies/RVTY. Each call links to attributed speakers and parsed analyst Q&A. REVVITY, INC.'s own investor relations page is at https://ir.revvity.com/home/default.aspx.
When was REVVITY, INC.'s most recent earnings call?
REVVITY, INC. (RVTY) held its most recent earnings call on 2026-05-05, covering fiscal Q1 2026.
What sector is RVTY in?
REVVITY, INC. (RVTY) operates in the Healthcare sector (Diagnostics & Research industry).